Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4040 Target Snapshot

Mitogen-activated protein kinase 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
24,434Compounds
1,003Assays
16Approved Drugs
11,218.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Mitogen-activated protein kinase 1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P28482. Start with neoplasm, then reuse UniProt P28482 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P28482 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
neoplasm

Mitogen-activated protein kinase 1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include MK-8353, RAVOXERTINIB, ULIXERTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase 1 as ChEMBL target CHEMBL4040, mapped to UniProt P28482. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4040
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P28482
Mitogen-activated protein kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase 1 is the right protein anchor across sources, using UniProt P28482 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as clinical signal support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMitogen-activated protein kinase 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP28482
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase 1
UniProt AccessionP28482
Component TypeProtein
Sequence Length360 aa

Mitogen-activated protein kinase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase 1, mapped to UniProt P28482. Sequence length is 360 aa.

Mapped IDP28482
Review nameMitogen-activated protein kinase 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Mitogen-activated protein kinase 1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
neoplasm
3 linked drugs · 3 direct · 3 efficacy
Linked drugMK-8353
Linked drugRAVOXERTINIB
Linked drugULIXERTINIB
Clinical signal Phase II
Uveal Melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugULIXERTINIB
Clinical signal Phase I
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugULIXERTINIB
Clinical signal Phase I
colorectal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMK-8353
Clinical signal Phase I
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugULIXERTINIB
Clinical signal Phase I
pancreatic carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugULIXERTINIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include MK-8353, RAVOXERTINIB, ULIXERTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

16
Approved
1
Phase III
17
Phase II
12
Phase I
Assay Mix

Activity Type Distribution

IC509,017.0
KI1,743.0
EC502.0
KD456.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3608588 11.0 IC50 0.01 Preclinical
CHEMBL4108345 11.0 IC50 0.01 Preclinical
CHEMBL4114147 11.0 IC50 0.01 Preclinical
CHEMBL4109252 10.99 IC50 0.0103 Preclinical
CHEMBL3957670 10.98 IC50 0.0104 Preclinical
CHEMBL4107945 10.97 IC50 0.0107 Preclinical
CHEMBL4109456 10.96 IC50 0.011 Preclinical
CHEMBL3923033 10.92 IC50 0.0119 Preclinical
CHEMBL4110508 10.92 IC50 0.0121 Preclinical
CHEMBL4108076 10.9 IC50 0.0127 Preclinical
Distribution

pChEMBL Value Distribution

178
5.0
245
5.5
460
6.0
816
6.5
755
7.0
908
7.5
1298
8.0
1169
8.5
564
9.0
247
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIVOZANIB
CHEMBL1289494
Approved 2017
Properties Compare Identifier
NALFURAFINE
CHEMBL267495
Approved 2009
Properties Compare Identifier
SORAFENIB
CHEMBL1336
Approved 2005
Properties Compare Identifier
ZAFIRLUKAST
CHEMBL603
Approved 1996
Properties Compare Identifier
TANNIC ACID
CHEMBL506247
Approved 1982
Properties Compare Identifier
ISOTRETINOIN
CHEMBL547
Approved 1982
Properties Compare Identifier
TRETINOIN
CHEMBL38
Approved 1971
Properties Compare Identifier
HEXACHLOROPHENE
CHEMBL496
Approved 1949
Properties Compare Identifier
TRIBROMSALAN
CHEMBL24944
Properties Compare Identifier
BITHIONOL
CHEMBL290106
Properties Compare Identifier
3,3',4',5-TETRACHLOROSALICYLANILIDE
CHEMBL291338
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,003
Total Assays
5,215
Tested Compounds
3
Assay Types
Binding — 988 assays, 5,215 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 812 4,898 7.9
assay format 117 199 7.7
cell-based format 41 112 6.3
subcellular format 16 5 6.4
cell-free format 2 1 6.4
Functional — 12 assays, 166 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 8 165 6.1
cell-based format 4 1 6.7
ADME — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 2 0 —
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine